L6H9 is a novel inhibitor of myeloid differentiation factor 2 (MD2), suppressing HG-induced expression of ACE and AT1 receptor and Angiotensin II (AngII) production in renal NRK‐52E cells, resulting in the decrease in fibrosis markers such as TGF-β and collagen IV.
Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone9, a quinolone alkaloid derived from Evodia rutaecarpa, is a potent antagonist of the angiotensin II receptor, displaying an IC50 value of 48.2 μM.